Table 1.
Characteristics of TEL-AML1-positive patients xenografted into NSG mice for analysis of p38α/β phosphorylation
| p-p38neg (n = 4) | p-p38pos (n = 8) | P | |
|---|---|---|---|
| Sexa | 1.000 | ||
| Male | 3 | 5 | |
| Female | 1 | 3 | |
| Median age (range) at diagnosis (years)b | 5.6 (4.7–13.3) | 4.8 (2.7–7.4) | 0.308 |
| Immunophenotypea | 1.000 | ||
| Common-ALL | 4 | 7 | |
| Pre-B-ALL | 0 | 1 | |
| WBC counta | 1.000 | ||
| <50 000/μl | 2 | 5 | |
| ≥50 000/μl | 2 | 3 | |
| Prednisone responsea,c | 1.000 | ||
| Good | 4 | 8 | |
| Poor | 0 | 0 | |
| Risk groupa,d | 0.067 | ||
| MRD-SR | 3 | 1 | |
| MRD-IR/-HR | 1 | 7 | |
| Extramedullary manifestation (initial)e | 1.000 | ||
| Yes | 0 | 0 | |
| No | 4 | 8 | |
| Relapsef | 0.002 | ||
| Yes | 0 | 8 | |
| No | 4 | 0 | |
| Deathg | 0.491 | ||
| Yes | 0 | 3 | |
| No | 4 | 5 |
Abbreviations: ALL, acute lymphoblastic leukemia; B-ALL, B-cell ALL; MRD-HR, minimal residual disease-high risk; MRD-IR, minimal residual disease-intermediate risk; MRD-SR, minimal residual disease-standard risk; WBC, white blood cells.
Fisher’s exact test, two-sided P-value.
Unpaired t-test with Welsh’s correction.
Good: less than 1000 leukemic blood blasts/μl on treatment day 8, poor: more than 1000/μl.
Risk stratification according to MRD risk groups: MRD-SR: time point (TP) 1+2 negative, MRD-IR: TP1 and/or TP2<10−3, MRD-HR: TP2> = 10 −3.
CNS 2/3 status, testicular involvement.
Five relapses were isolated bone marrow relapses. One relapse was a combined bone marrow/CNS relapse. One relapse was an isolated testicular relapse, one was an isolated CNS relapse. Two patients had two relapses, both of which were bone marrow relapses.
All deaths were related to the relapse. One patient died from pontine infarction at relapse, one from post-SCT bronchiolitis obliterans organizing pneumonia and one patient from sepsis.